TICKERNERD
Menu
OSRHOSRHHealthcare · Biotechnology

OSRH Stock Forecast: OSR Health, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$0.45
−0.42% on the day

The 1 Wall Street analysts covering OSR Health, Inc. hold a median 12-month price target of $10 — +2141.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$15.7M
Ticker Nerd rank
23 / 100
Median analyst target
$10
Analysts covering
1
Total return, dividends reinvested
1W
+3.0%
1M
+39.0%
YTD
−20.9%
1Y
−30.5%
From 52W high
−55.8%
From 52W low
+44.8%
$0.31
$1.01
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OSRH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OSR Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Accruals
68
Growth
60
Volatility
39
Momentum
27
Revisions
25
Issuance
24
Quality
21
Value
12

Size (89): Smaller than most of the companies we track.

Value (12): The shares cost a lot relative to the profits and assets behind them.

The rank is the raw material. Whether the rules would actually own OSR Health, Inc. — and when they’d sell — is the membership.

Wall Street

OSRH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OSRH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26OSRHHigh $10Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $10Median $10High $10

The green dot is the last close — the median target sits +2141.6% from it.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

OSRH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

OSR Health, Inc. (OSRH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.9×

Cheaper than 47% of US stocks

Price / sales
6.0×

Cheaper than 21% of US stocks

Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
−4.4×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
−36.4%

Higher than 7% of US stocks

Earnings growth (YoY)
−36.4%

Higher than 13% of US stocks

Gross margin
33.1%

Higher than 41% of US stocks

Operating margin
−757.6%

Higher than 7% of US stocks

Net margin
20.4%

Higher than 83% of US stocks

Returns & dividend
Return on equity
−14.7%

Higher than 33% of US stocks

Return on assets
−6.9%

Higher than 29% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OSRH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OSRHOSR Health, Inc.$15.7M
23
CTXRCitius Pharmaceuticals, Inc.$15.6M
27
KTTAPasithea Therapeutics Corp.$15.4M
21
CYCNCyclerion Therapeutics, Inc.$16.1M
25
NRSNNeurosense Therapeutics Ltd.$16.4M
2
HINDVyome Holdings, Inc.$14.8M
42
PLURPluri, Inc.$16.7M
12
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSRH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest OSRH news & analysis

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Accesswire · 3 Aug 2026positive

OSR Health, Inc. announced that its subsidiary Vaximm AG has completed analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting VEGFR-2, in patients with recurrent glioblastoma. Encouraging data from these studies are expected to be submitted for publication in the coming months.

Why it matters — OSRH watchers would care because the subsidiary's VXM01 platform has produced encouraging clinical data in glioblastoma, marking a potential pipeline milestone at a major news event.

OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment

Accesswire · 31 July 2026positive

Nasdaq verbally informed OSR Health that its Shareholder Loyalty Contingent Value Rights program will not trigger a mechanical price adjustment to the company's common stock upon distribution or delivery of additional shares.

Why it matters — OSRH watchers concerned about potential dilution or price impact from the CVR program now have clarity that no automatic price adjustment will occur.

FAQ

Frequently asked questions about OSRH stock

What is the OSRH stock price forecast for 2026-2027?

The 1 Wall Street analysts covering OSR Health, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OSRH stock a buy right now?

Of the 1 analysts covering OSR Health, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OSR Health, Inc. 23 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OSRH?

As at 1 Aug 2026, OSR Health, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will OSRH stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +2141.6% from the last close, and Ticker Nerd's factor model ranks OSR Health, Inc. 23 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OSRH stock forecast for 2030?

No analyst covering OSR Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSRH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.

How has OSRH stock performed over the past year?

OSR Health, Inc. returned -30.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OSR Health, Inc. do?

OSR Holdings Inc. is a healthcare holding company operating a hub-and-spoke model with wholly owned subsidiaries focused on advancing biomedical innovations across immuno-oncology, regenerative biologics, noninvasive glucose monitoring, and medical device distribution.

What is the latest news on OSRH?

The most recent item we track (Accesswire, 3 Aug 2026): "Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform". OSR Health, Inc. announced that its subsidiary Vaximm AG has completed analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting VEGFR-2, in patients with recurrent glioblastoma. Encouraging data from these studies are expected to be submitted for publication in the coming months.

Company

About OSR Health, Inc.

OSR Holdings Inc. is a healthcare holding company operating a hub-and-spoke model with wholly owned subsidiaries focused on advancing biomedical innovations across immuno-oncology, regenerative biologics, noninvasive glucose monitoring, and medical device distribution. Through subsidiaries like Vaximm AG, it develops oral T-cell immunotherapies targeting tumor vasculature, including candidates such as VXM01 for glioblastoma in phase 2 trials, and preclinical products addressing mesothelin, WT1, CEA, and PD-L1. In regenerative biologics, it advances design-augmented assets like DRT-102 for spinal fusion and DRT-101 for osteoarthritis. Woori IO Co., Ltd. pioneers needle-free glucose monitoring using near-infrared spectroscopy technology, while another segment distributes neurovascular intervention systems in South Korea. Headquartered in Bellevue, Washington, with operations in the United States, Switzerland, and South Korea, OSR Holdings Inc. centralizes expertise to support its portfolio, emphasizing simplification through innovation to develop differentiated treatments for cancer, degenerative diseases, diabetes management, and neurovascular conditions.

CEO Mr. Kuk Hyoun Hwang · 22 employees · United States · https://osr-holdings.com